We invest in people.

In Life Sciences
and Chemistry.

Our
Track Record

Life Sciences and Chemistry

“HTGF is very supportive and easy to work with.
They foster a collaborative environment and respond very fast to any request.

David Neale

Founder and CEO of Argá Medtech

Spotlight
Life Sciences & Chemistry

8 of 500 Companies
2022

EEDEN

North Rhine-Westphalia
Recycling

EEDEN starts upcycling – turning textile waste into valuable ressources for new fibres. The Company developed a chemical upcycling process for textile waste, recovering its resources. In this way, new, …

To the complete profileof EEDEN
2021

Argá Medtech

Life Sciences

Argá Medtech, developing the next generation Cardiac Ablation system for the treatment of Atrial Fibrillation and other arrhythmias. A safer, simpler, faster and more effective procedure for the benefit of …

To the complete profileof Argá Medtech
2020

Tubulis

Bavaria
Oncology

Tubulis generates uniquely matched protein-drug conjugates by combining proprietary novel technologies with disease-specific biology. Our goal is to expand the therapeutic potential of antibody drug conjugates (ADCs) ushering in a …

To the complete profileof Tubulis
2019

Biograil

International
Drug Delivery

Biograil is a Danish start-up using injection molding to manufacture a device contained in a standard size capsule able to deliver active substances into the gastrointestinal wall. The Biograil device …

To the complete profileof Biograil
2019

Emergence Therapeutics

North Rhine-Westphalia
Exit
Oncology

Development of antibody conjugate-based cancer therapeutics for solid tumors with high unmet needs that are otherwise difficult to treat Problem: Solid cancers are still very difficult to treat. Most treatments …

To the complete profileof Emergence Therapeutics
2017

CARDIOR

Lower Saxony
Exit
Cardiology / Cardiovascular

Cardior is focused on the development and clinical validation of ncRNA therapeutics for patients with myocardial infarction and heart failure. Cardior aims to market its products in collaboration with a …

To the complete profileof CARDIOR
2011

MYR

Lower Saxony
Exit
Pharmaceuticals

MYR, acquired by Gilead Sciences in 2021, developed a peptide-based, first-in-class drug to combat chronic hepatitis B and delta. The drug has been approved by the EMA for the treatment …

To the complete profileof MYR
2006

c-LEcta

Saxony
Exit
Industrial Biotech

c-LEcta is a leading biotechnology company located in Leipzig, Germany. The company has established itself as a leading player in the realisation of high-value biotechnology products for regulated markets, either …

To the complete profileof c-LEcta
3 of 500 Companies

Tomorrows market will be different
We invest now

Pharma, BioTech, R&D Tools and Diagnostics

Germany is one of the global leaders in life science research. We invest in disruptive technologies and visionaries not only to further innovation, but also to actively shape the market.

MedTech and Digital Health

Societal challenges such as demographic change, the shortage of skilled workers or complex diseases demand visionary answers. Together, we transform these into market-relevant solutions.

Chemistry

How do we feed a growing world population in the future, how do we counter the effects of climate change? We believe in the answers provided by science – and we know the challenges of lab-to-market startups from our own experience.

Success stories
People invest in People

Last update 2 days ago
Zum Artikel

News

7. April 2025

Successful exit for HTGF: German Medical Engineering joins the Thomas Group 

Zum Artikel

News

29. October 2024

Aignostics Secures $34 Million Series B to Enhance Precision Medicine with AI

Zum Artikel

News

25. March 2024

Successful exit for HTGF: Novo Nordisk to acquire Cardior Pharmaceuticals

Zum Artikel

News

14. March 2024

Tubulis Closes Upsized €128 Million Series B2 to Accelerate Clinical Development of Solid Tumor-Focused ADC Pipeline

EEDEN Founders Zum Artikel

News

22. June 2022

TechVision Fonds I and High-Tech Gründerfonds invest in textile recycling startup EEDEN

Zum Artikel

News

15. February 2022

Very Successful Exit for High-Tech Gründerfonds – Kerry acquires c-LEcta

Zum Artikel

News

7. December 2021

Emergence Therapeutics raises €87 million Series A financing to advance Nectin-4 ADC

Science-driven with entrepreneurial spirit
The Life Sciences & Chemistry Team

Zum Artikel

Dr. Angelika Vlachou Partner

Dr. Angelika VlachouPartner

Zum Artikel

Dr. Bernd Goergen Partner

Dr. Bernd GoergenPartner

Zum Artikel

Marco Winzer Partner

Marco WinzerPartner

Zum Artikel

Dr. Anke Caßing Principal

Dr. Anke CaßingPrincipal

Zum Artikel

Dr. Caroline Fichtner Principal

Dr. Caroline FichtnerPrincipal

Zum Artikel

Kay G. Balster Principal

Kay G. BalsterPrincipal

Zum Artikel

Dr. Frank Hensel Principal

Dr. Frank HenselPrincipal

Zum Artikel

Dr. Nikolaus Raupp Principal

Dr. Nikolaus RauppPrincipal

Zum Artikel

Dr. Laura Pedroza Senior Investment Manager

Dr. Laura PedrozaSenior Investment Manager

Zum Artikel

Dr. Christian Kannemeier Senior Investment Manager

Dr. Christian KannemeierSenior Investment Manager

Zum Artikel

Dr. Natalya Baltrukovich Investment Manager

Dr. Natalya BaltrukovichInvestment Manager

Zum Artikel

Dr. Lena-Sophie Schütter Investment Manager

Dr. Lena-Sophie SchütterInvestment Manager

Zum Artikel

Dr. Katharina Severin Investment Manager

Dr. Katharina SeverinInvestment Manager

Zum Artikel

Dr. Jan Engels Investment Manager

Dr. Jan EngelsInvestment Manager

Zum Artikel

Tilmann Petersen Investment Manager

Tilmann PetersenInvestment Manager

Zum Artikel

Stephan Ruck Investment Analyst

Stephan RuckInvestment Analyst

Zum Artikel

Jonas von der Decken Junior Analyst

Jonas von der DeckenJunior Analyst

Added Value.
The HTGF promise

We see the potential for real innovation before anyone else does – with a deep understanding of the market and excellent connections to research, institutes and universities. We are the door opener that your start-up needs in the financing round to revolutionise the market.

We invest
first.

open/close

Early-stage investments are at the heart of our business: we take early ristks on to ensure that your solution gets market ready.

Bridge-building: from science to venture.

open/close

As a diverse team drawn from science, medicine and entrepreneurs, we are familiar with the challenges you face – including those that await you tomorrow.

Our network is your superpower.

open/close

With our large network and over 45 companies invested in the fund, you will find the right partners to drive your business forward.

770 Ventures, one HTGF family.

open/close

Talents are your resource for success, collaborations your lever for transformation. Join the family – and grow beyond yourself.

Its you
who can change the world.

We have helped some of Germany’s most innovative companies get off the ground. We are the right partner for you, too, if…

  • you are R&D-based, but your business network needs to be expanded.
  • you have an innovative solution, technology or patent, but your lab-to-market strategy needs to be built.
  • your company is facing regulatory hurdles that overwhelm your team resources.
  • you are in an early phase and need a strong consortium for the challenging development.

Do you want to found in

Life Sciences or Chemistry?

Is your Pitch deck

ready to go?